• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ethos Reports First Quarter Fiscal Year 2026 Financial Results

    5/6/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance
    Get the next $LIFE alert in real time by email
    • Q1 Revenue grew 104% year-over-year to $193 million
    • Q1 Direct Channel Revenue grew 136% year-over-year to $146 million
    • Q1 Third-Party Revenue grew 42% year-over-year to $47 million



    AUSTIN, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the first quarter ended March 31, 2026.     

    "Q1 is our seasonally strongest quarter, and this was an exceptional one," said Peter Colis, CEO and Co-Founder of Ethos. "Our results reflect both the velocity of our growth and the discipline of our execution. We are committed to protecting families at scale, and in Q1 we protected more than 88,000 additional families."

    First Quarter 2026 Financial Highlights

    • Revenue: Grew 104% year-over-year to $193.1 million
    • Direct Channel Revenue: Grew 136% year-over-year to $146.0 million with similar year-over-year unit economics
    • Third-Party Channel Revenue: Grew 42% year-over-year to $47.1 million
    • Net Loss: $(166.4) million, representing a (86)% margin
    • Non-GAAP Net Income: $29.1 million, representing a 15% margin
    • Adjusted EBITDA: $33.6 million, representing a 17% margin
    • Gross Profit: $189.9 million, representing a 98% gross profit margin
    • Contribution Profit: $58.6 million, a 30% contribution profit margin
    • Net Loss per Share: basic and diluted, was $(3.57) per share
    • Non-GAAP Net Income per Share: diluted was $0.38 per share    
    • Cash Flow: $31.2 million net cash provided by operations



    First Quarter 2026 Business Highlights

    • Families Protected: Activated 88,373 new policies in Q1, representing 84% year-over-year growth
    • Reported Average Revenue per Unit: $2,185, representing 11% year-over-year growth
    • Product Innovation: Launched two new Whole Life products with Banner Life



    Agent Payments Update

    During Q1, Ethos updated its third-party agent compensation and persistency estimates to reflect both maturing cohort experience and the impact of recent operational improvements. As these cohorts matured and additional observed experience accumulated, Ethos identified that early-stage policy persistency was better than originally projected. Together with the impact of recent operational improvements, these factors resulted in lower agent compensation clawbacks and, therefore, higher agent compensation expense than originally projected for policies activated through the company's Third-Party channel in the second half of 2024 and throughout 2025.

    The resulting change in estimate resulted in a one-time, non-cash charge of $16.5 million in Q1.

    Financial Outlook     

    For the second quarter of 2026, Ethos expects the following:

    • Total Revenue: Between $114.0 million and $118.0 million, representing a 31% increase year-over-year at the midpoint
    • Adjusted EBITDA: Between $20.0 million and $22.0 million

    For the full fiscal year 2026, Ethos expects the following:

    • Total Revenue: Between $561.0 million and $565.0 million, representing a 45% increase year-over-year at the midpoint
    • Adjusted EBITDA: Between $103.0 million and $107.0 million

    Ethos' financial outlook for the second quarter and full fiscal year 2026 are forward-looking, and actual results may differ materially as a result of many factors. Refer to the Forward-Looking Statements safe harbor below for information on the factors that could cause the company's actual results to differ materially from these forward-looking statements.

    Reconciliation of Adjusted EBITDA on a forward-looking basis to net income, the most directly comparable GAAP measure, is not available without unreasonable efforts due to high variability and complexity and low visibility with respect to certain charges excluded from this non-GAAP measure, including interest expense and interest income and income tax expenses. Ethos expects the variability of these items could have a significant, and potentially unpredictable, impact on its future GAAP financial results.

    Conference Call Information

    Ethos will host a conference call for analysts and investors to discuss its earnings results for the first quarter 2026 and outlook for its second fiscal quarter and fiscal year 2026 today at 1:30 p.m. Pacific time (4:30 p.m. Eastern time). A live webcast and accompanying presentation can be accessed through the events section of the Ethos investor relations website at investors.ethos.com. A recorded webcast of the event will also be available on the Ethos Investor Relations website.

    Non-GAAP Financial Information

    Ethos has provided in this press release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). We believe that non-GAAP financial measures, among others, provide important supplemental information to management and investors, help evaluate our business, identify trends affecting our performance, formulate business plans, and make strategic decisions.

    The presentation of these non-GAAP financial measures is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP. For further information regarding these non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to the financial tables below.

    Adjusted EBITDA - Ethos defines Adjusted EBITDA as net income excluding interest expense, interest income, income tax expense, depreciation and amortization, and stock-based compensation expense and related taxes as set forth in the table below. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA for a period by revenue for the same period. Ethos uses Adjusted EBITDA and Adjusted EBITDA Margin to assess performance, to inform the preparation of its annual operating budget and quarterly forecasts, to evaluate the effectiveness of its business strategies, and to assist its board of directors in monitoring its business and financial performance. Ethos believes that Adjusted EBITDA and Adjusted EBITDA Margin provide useful information to investors about its business and financial performance, enhance their overall understanding of its past performance and future prospects, including by providing consistency and comparability with its past financial performance, and allow for greater transparency with respect to measures used by its management in investors' financial and operational decision making. In addition, Ethos believes Adjusted EBITDA is widely used by investors, securities analysts, and other parties in evaluating companies in its industry as a measure of operational performance.

    Contribution Profit - Ethos defines Contribution Profit as gross profit less sales and marketing expense, which includes agent payments and underwriting costs for non-activated policies, plus stock-based compensation and related taxes related to its employees and overhead costs allocated to sales and marketing expenses. Gross profit is defined as revenue less cost of revenue. Cost of revenue primarily consists of underwriting costs associated with activated policies. Overhead costs allocated to sales and marketing expenses include professional fees, technology expenses, and other related costs. Contribution Margin is calculated by dividing Contribution Profit for a period by revenue for the same period.

    Non-GAAP Net Income and Non-GAAP Net Income Per Share, Basic and Diluted - Ethos defines non-GAAP net income as net income, adjusted to exclude stock-based compensation and related taxes, in order to provide investors and management with greater visibility to the underlying performance of its recurring core business operations. Ethos defines non-GAAP net income per share, basic, as non-GAAP net income divided by the weighted-average shares outstanding. Ethos defines non-GAAP net income per share, diluted, as non-GAAP net income divided by the weighted-average shares outstanding, which includes the dilutive effect of potentially diluted common stock equivalents outstanding during the period, if any.     

    About Ethos

    Ethos is a leading life insurance technology company on a mission to protect families by democratizing access to life insurance and empowering agents at scale. With its robust three-sided technology platform, Ethos is transforming the life insurance experience for consumers, agents, and carriers alike. Ethos offers instant, accessible products and a seamless online process that requires no medical exams and just a few health questions; it eliminates traditional barriers, making it easier than ever for everyone to protect their families. Ethos is redefining how life insurance is bought, sold, and underwritten.

    Learn more at ethos.com.

    Investor Relations Contact:

    Aaron Turner

    ir@ethos.com 

    Press Contact:

    Allyson Savage

    press@ethos.com

    Forward-Looking Statements

    This press release and the related conference call contain express and implied "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Ethos' financial outlook for the fiscal quarter ending June 30, 2026 and the fiscal year ending December 31, 2026, the size of Ethos' market opportunity, market trends, and Ethos' business and financial strategy and plans. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project," "will," or similar expressions. Such statements are subject to risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. These include, but are not limited to: Ethos' limited operating history at its current scale, scope and complexity; the growth rate of the markets in which Ethos competes; Ethos' ability to effectively manage and sustain its growth; Ethos's ability to compete with existing competitors and new market entrants; Ethos' ability to attract new and retain existing carriers and agency counterparties; adoption of and engagement with Ethos' platform by individual agents; Ethos' brand awareness and the success of its marketing efforts to grow its business; potential damage to Ethos' reputation; disruptions or other business interruptions that affect the availability of Ethos' platform. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements contained herein are included in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Ethos' most recent filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Except as required by law, Ethos undertakes no obligation, and does not intend, to update these forward-looking statements.



    ETHOS TECHNOLOGIES INC.

    Condensed Consolidated Statements of Operations

    (In Thousands, Except Per Share Data) (Unaudited)

     
      Three Months Ended March 31, 
      2026  2025 
    Revenue:      
    Commission $193,099  $94,888 
    Total revenue  193,099   94,888 
    Costs and expenses:      
    Sales and marketing  144,107   56,383 
    General and administrative  180,644   13,396 
    Technology (exclusive of amortization)  27,063   9,658 
    Cost of revenue  3,230   1,575 
    Depreciation and amortization  1,369   1,337 
    Total costs and expenses  356,413   82,349 
    Income (loss) from operations  (163,314)  12,539 
    Other income (expense):      
    Interest expense  (662)  (973)
    Interest income  1,377   1,513 
    Other income, net  53   32 
    Total other income, net  768   572 
    Net income (loss) before income tax expense  (162,546)  13,111 
    Income tax expense  (3,845)  (864)
    Net income (loss)  (166,391)  12,247 
    Deemed dividend on the conversion of Series D and D1 redeemable convertible preferred stock  (5,642)  — 
    Net income (loss) attributable to common stockholders $(172,033) $12,247 
           
    Per share data:      
    Basic net income (loss) per share $(3.57) $0.75 
    Diluted net income (loss) per share $(3.57) $0.21 
    Weighted-average shares used in computing basic net income (loss) per share  48,130   16,260 
    Weighted-average shares used in computing diluted net income (loss) per share  48,130   58,762 

         

    ETHOS TECHNOLOGIES INC.

    Condensed Consolidated Balance Sheets

    (In Thousands) (Unaudited)

     
      March 31,  December 31, 
      2026  2025 
    Assets      
    Current assets:      
    Cash and cash equivalents $107,909  $91,091 
    Short-term investments  36,692   34,876 
    Accounts receivable, net  53,337   36,498 
    Commissions receivable-current, net  26,382   28,786 
    Prepaid and other current assets  35,032   54,553 
    Total current assets  259,352   245,804 
    Long-term assets:      
    Commissions receivable, net  265,021   224,219 
    Property and equipment, net  10,288   8,189 
    Operating lease right-of-use assets  1,892   2,183 
    Goodwill  2,238   2,238 
    Acquired intangible assets, net of amortization  637   662 
    Long-term investments  79,203   31,468 
    Other long-term assets  733   574 
    Total long-term assets  360,012   269,533 
    Total assets $619,364  $515,337 
    Liabilities, redeemable preferred stock and stockholders' equity      
    Current liabilities:      
    Accounts payable $65,908  $55,070 
    Accrued expenses  53,026   39,224 
    Liabilities related to sale of commissions receivable-current  10,724   11,750 
    Operating lease liabilities-current  1,129   1,125 
    Other current liabilities  24,170   6,021 
    Total current liabilities  154,957   113,190 
    Long-term liabilities:      
    Liabilities related to sale of commissions receivable-non-current  10,459   12,509 
    Operating lease liabilities-non-current  922   1,228 
    Deferred tax liability  11,703   8,529 
    Total long-term liabilities  23,084   22,266 
    Total liabilities  178,041   135,456 
    Commitments and contingencies      
    Redeemable convertible preferred stock, par value $0.0001  —   403,997 
    Stockholders' deficit:      
    Common stock, $0.0001 par value  6   2 
    Additional paid-in capital  711,325   78,950 
    Accumulated other comprehensive loss  (1,103)  (554)
    Accumulated deficit  (268,905)  (102,514)
    Total stockholders' equity (deficit)  441,323   (24,116)
    Total liabilities, redeemable convertible preferred stock and stockholders' equity $619,364  $515,337 



    ETHOS TECHNOLOGIES INC.

    Condensed Consolidated Statements of Cash Flows

    (In Thousands) (Unaudited)

     
      Three Months Ended March 31, 
      2026  2025 
    Cash flows from operating activities      
    Net income (loss) $(166,391) $12,247 
    Adjustments to reconcile net income to net cash used in operating activities:      
    Deferred taxes  3,174   644 
    Depreciation and amortization  1,347   1,337 
    Non-cash interest expense  661   973 
    Amortization of discounts and premium, investments  (182)  (432)
    Stock-based compensation expense  192,724   9,814 
    Operating lease right-of-use asset amortization  256   227 
    Unrealized foreign currency translation  (112)  (119)
    Changes in operating assets and liabilities:      
    Prepaid and other assets  12,389   (7,963)
    Accounts payable  9,952   10,178 
    Accounts receivable  (16,839)  (8,927)
    Commissions receivable  2,404   (1,251)
    Long-term commissions receivable  (40,802)  (16,483)
    Accrued expenses  14,746   5,949 
    Other current liabilities  17,882   4,616 
    Net cash provided by operating activities  31,209   10,810 
    Cash flows from investing activities      
    Purchase of property and equipment  (353)  (278)
    Purchase of investments  (77,187)  (22,210)
    Proceeds from maturity of investments  27,015   25,200 
    Investment in software development costs  (1,573)  (737)
    Net cash provided by (used in) investing activities  (52,098)  1,975 
    Cash flows from financing activities      
    Proceeds from issuance of Class A common stock in initial public offering, net of

    underwriting discounts and commissions
      91,580   — 
    Proceeds from liabilities related to sale of commissions receivable  —   5,000 
    Taxes paid related to net share settlement of restricted stock units  (49,085)  — 
    Repayment of liabilities related to sale of commissions receivable  (3,573)  (2,172)
    Proceeds from exercise of stock options and warrants  666   719 
    Payment of deferred offering costs  (1,804)  (156)
    Net cash provided by financing activities  37,784   3,391 
    Net increase in cash and cash equivalents  16,895   16,176 
    Effect of exchange rates on cash  (77)  (4)
    Cash and cash equivalents, beginning of period  91,091   35,075 
    Cash and cash equivalents, end of period $107,909  $51,247 



    ETHOS TECHNOLOGIES INC.

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

    (In Thousands) (Unaudited)

     
      Three Months Ended March 31, 
      2026  2025 
      (in thousands) 
    Gross profit $189,869  $93,313 
    Less: sales and marketing  (144,107)  (56,383)
    Add: stock-based compensation and related taxes allocated to sales and marketing  10,364   1,987 
    Add: professional fees allocated to sales and marketing  327   366 
    Add: technology expenses allocated to sales and marketing  1,211   796 
    Add: other expenses allocated to

    sales and marketing
      935   392 
    Contribution profit $58,599  $40,471 
    Contribution profit margin  30%  43%



      Three Months Ended March 31, 
      2026  2025 
      (in thousands) 
    Net income (loss) before provision for income tax $(162,546) $13,111 
    Interest expense  662   973 
    Interest income  (1,377)  (1,513)
    Depreciation and amortization  1,369   1,337 
    Stock–based compensation and related taxes  195,507   9,814 
    Adjusted EBITDA $33,615  $23,722 
    Adjusted EBITDA margin  17%  25%



      Three Months Ended March 31, 
      2026  2025 
      (in thousands) 
    Stock–based compensation and related taxes      
    Sales and marketing $10,364  $1,987 
    General and administrative  168,104   5,474 
    Technology (exclusive of amortization)  17,039   2,353 
    Total $195,507  $9,814 



      Three Months Ended March 31, 
      2026  2025 
      (in thousands, except per share data) 
    GAAP net income (loss) $(166,391) $12,247 
    Deemed dividend on the conversion of Series D and D1 redeemable convertible preferred stock  (5,642)  — 
    GAAP net income (loss) attributable to common stockholders $(172,033) $12,247 
             
    GAAP net income (loss) $(166,391) $12,247 
    Add back: Stock-based compensation expense and related taxes  195,507   9,814 
    Non GAAP net income $29,116  $22,061 
    Deemed dividend on the conversion of Series D and D1 redeemable convertible preferred stock  (5,642)  — 
    Non-GAAP net income attributable to common stockholders $23,474  $22,061 
           
    Per share data:      
    Weighted-average shares used in computing GAAP net income (loss) per share, basic  48,130   16,260 
    Weighted-average shares used in computing GAAP net income (loss) per share, diluted  48,130   58,762 
    Weighted-average shares used in computing non-GAAP net income per share, basic  48,130   16,260 
    Weighted-average shares used in computing non-GAAP net income per share, diluted  62,269   58,762 
           
    GAAP net income (loss) per share attributable to common stockholders, basic $(3.57) $0.75 
    GAAP net income (loss) per share attributable to common stockholders, diluted $(3.57) $0.21 
    Non-GAAP net income per share attributable to common stockholders, basic $0.49  $1.36 
    Non-GAAP net income per share attributable to common stockholders, diluted $0.38  $0.38 





    Primary Logo

    Get the next $LIFE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    2/23/2026$33.00Buy
    Goldman
    2/23/2026$18.00Outperform
    Robert W. Baird
    2/23/2026$21.00Mkt Outperform
    Citizens
    2/23/2026$20.00Overweight
    Barclays
    2/23/2026$23.00Buy
    Deutsche Bank
    2/23/2026$13.00Overweight
    Analyst
    2/23/2026$15.00Buy
    Citigroup
    2/23/2026Outperform
    William Blair
    More analyst ratings

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Wang Lingke sold $1,024,561 worth of shares (46,349 units at $22.11), decreasing direct ownership by 14% to 695,302 units (SEC Form 4) (withholding tax)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    5/19/26 8:34:42 PM ET
    $LIFE
    Specialty Insurers
    Finance

    CEO and Secretary Colis Peter George sold $1,324,783 worth of shares (60,035 units at $22.07), decreasing direct ownership by 14% to 695,302 units (SEC Form 4) to satisfy withholding obligation

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    5/19/26 8:32:49 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Chief Financial Officer Capozzi Christopher M. was granted 80,287 shares and sold $1,783,698 worth of shares (80,586 units at $22.13), decreasing direct ownership by 0.04% to 665,228 units (SEC Form 4) (tax liability)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    5/19/26 8:31:21 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ethos Partners with Baseball Legend David Ortiz to Champion Life Insurance as a Family Financial Essential

    AUSTIN, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a new partnership with baseball icon and 3x world champion David Ortiz. In a new campaign, Ortiz will share his profoundly personal story to help raise awareness about why life insurance can be an essential part of every family's financial protection plan—and how Ethos makes getting that coverage simple, fast, and accessible. "I've lost people I love more than anything, and I've almost lost my own life," said David Ortiz. "When you go through something like that, you stop thinking about tomorrow and start thinking about th

    5/21/26 9:07:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos to Present at Upcoming Investor Conferences

    AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive Officer, will present at the following investor conferences. Event Details: Bank of America Global Technology Conference on June 2, 2026 at 2:00 p.m. PT / 5:00 p.m. ETBaird 2026 Global Consumer, Technology & Services Conference on June 3, 2026 at 11:00 a.m. PT / 2:00 p.m. ETWilliam Blair 46th Annual Growth Stock Conference on June 4, 2026 at 7:20 a.m. PT / 10:20 a.m. ET A live webcast of the presentations will be available on Ethos's investor relations website at investor

    5/15/26 4:30:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos Announces Early Lock-Up Release

    Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the applicable price condition for a partial early lock-up release pursuant to the terms of the lock-up agreements entered into in connection with Ethos's initial public offering has been satisfied. As a result, 25% of the eligible securities held by eligible holders as of February 15, 2026 ("Eligible Securities") will be automatically released from the lock-up restrictions immediately prior to opening of trading on May 14, 2026 and may be sold into the public market. The lock-up restrictions will continue to apply to all remaining shares subject to lock-u

    5/13/26 4:35:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Botha Roelof bought $4,949,975 worth of shares (260,525 units at $19.00), converted options into 12,000,124 shares and returned 12,000,124 shares to the company (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:36:37 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Wheeler William J bought $4,949,975 worth of shares (260,525 units at $19.00), increasing direct ownership by 2,481% to 271,025 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:49:26 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Mullin Mark W. bought $99,997 worth of shares (5,263 units at $19.00), increasing direct ownership by 43% to 17,451 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:48:09 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Ethos Technologies with a new price target

    Goldman initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $33.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Robert W. Baird initiated coverage on Ethos Technologies with a new price target

    Robert W. Baird initiated coverage of Ethos Technologies with a rating of Outperform and set a new price target of $18.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Citizens initiated coverage on Ethos Technologies with a new price target

    Citizens initiated coverage of Ethos Technologies with a rating of Mkt Outperform and set a new price target of $21.00

    2/23/26 8:36:59 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Ethos Technologies Inc.

    SCHEDULE 13G - Ethos Technologies Inc. (0001788451) (Subject)

    5/15/26 9:00:02 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 144 filed by Ethos Technologies Inc.

    144 - Ethos Technologies Inc. (0001788451) (Subject)

    5/15/26 6:00:42 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 144 filed by Ethos Technologies Inc.

    144 - Ethos Technologies Inc. (0001788451) (Subject)

    5/15/26 5:59:47 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin

    7/30/25 11:00:00 AM ET
    $EVR
    $LIFE
    $ATH
    Investment Managers
    Finance
    Specialty Insurers
    Life Insurance

    aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

    SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

    1/18/24 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/14/24 1:43:55 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/13/24 4:30:17 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/9/24 8:35:54 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Financials

    Live finance-specific insights

    View All

    Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026

    AUSTIN, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will release its financial results for the first quarter of 2026, which ended March 31, 2026, following the close of U.S. financial markets on Wednesday, May 6, 2026. The company's earnings press release will be made available on the Ethos Investor Relations website at investors.ethos.com. Ethos executives will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET the same day. The live webcast of the conference call can be found on the Ethos Investor Relatio

    4/2/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Records full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers third consecutive year of revenue growth greater than 50% AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial resul

    2/25/26 4:05:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

    3/14/24 4:00:00 PM ET
    $LIFE
    Specialty Insurers
    Finance